AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 221 min read$BHVN

Biohaven Ltd. Stock 12‑Month Price Target Raised to $24.92, Implies 112% Upside

Biohaven Ltd.'s average stock price target increased from $24.42 to $24.92, with a range of $10 to $48, implying 112% upside. 14 analysts maintain a 'Buy' consensus, with 10 Buys, 3 Holds, and 1 Sell.

Original reporting
tradingview.com
Published Oct 22, 2026, 10:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 10:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Biohaven Ltd. Stock 12‑Month Price Target Raised to $24.92, Implies 112% Upside — source image
Source · tradingview.com
Decision brief

The 30-second read

$BHVNBullishLow
01

Why it matters

A modest upward revision that may marginally influence short‑term trading sentiment.

02

Market read

Small‑cap biotech price target update with limited trading impact.

03

What to watch

Potential upcoming clinical trial results could alter the outlook beyond the current target.

Relevance 4/10Novelty 3/10Timing: today

Background

The article aggregates recent analyst price target estimates for Biohaven Ltd.

Company-level read

Ticker impact

$BHVNBullishMedium confidence
Context

Analyst consensus raised Biohaven's average price target to $24.92, implying 112% upside.

Expected impact

likely upward pressure as investors price in the higher target

Evidence & confidence

The new target is a fresh analyst consensus, but the magnitude is modest and no immediate catalyst beyond the rating change.

Market effects

Sector

Minimal; the target change is specific to Biohaven and does not affect the broader biotech sector.

Regional

None; the news is company‑specific.

Global

Low; no macro or global impact.

Counterpoint

What could challenge this read

Investors may view the target raise as overly optimistic given limited new data.

Key entities

  • company
    Biohaven Ltd.

    Biopharmaceutical company focused on neurology.

Read at source← All news

Related articles

OCT 26
$BHVNMedAI 8/10

Biohaven presents preclinical data on kidney disease drug candidate

Biohaven Ltd. (NYSE:BHVN) presented preclinical data for BHV-1420, a drug candidate for kidney disease, at the American Society of Nephrology Kidney Week 2026. The data showed promising results in tests and mouse models, targeting autoantibodies in membranous nephropathy. The company is exploring partnerships for its nephrology franchise, which includes BHV-1400 for IgA nephropathy. BHV-1420 is still in preclinical development.

investing.com2 min
OCT 22
$BHVNHighAI 8/10

Biohaven’s previously rejected rare disease drug to get fresh FDA review

Biohaven's Vyglxia, a drug for spinocerebellar ataxia, will undergo a fresh FDA review after a previous rejection. The FDA will convene an expert panel and issue a decision in Q1 2024. Biohaven claims to have submitted new supportive analyses. The announcement caused a 25% rise in shares and optimistic analyst notes, with some predicting over $1 billion in annual sales if approved.

finance.yahoo.com2 min
OCT 22
$BHVNHighAI 8/10

Biohaven Stock Soars Nearly 30% After FDA Accepts Resubmitted Application for Rare Disease Drug Vyglxia

Biohaven Ltd. shares rose 29.62% to $15.23 after the FDA accepted its resubmitted application for Vyglxia, a treatment for spinocerebellar ataxia. The FDA set a decision deadline for Q1 2027. Biohaven had previously faced regulatory setbacks, including a 28% stock decline over the past year. The company has no revenue and a trailing loss of $4.65 per share.

ibtimes.com.au2 min